10.1016/j.freeradbiomed.2017.10.372 106 SugiuraT.KatoS.ShimizuT.WakayamaT.NakamichiN.KuboY.et al (2010)
About this article Cite this article Pahal, S., Gupta, A., Kumar, V
Preliminary data published in June 2023 also suggests that GLP-1 drugs 'could modulate crucial pathways in the pathogenesis of inflammatory bowel disease (IBD), such as chronic inflammation circuits, intestinal tight junctions, and gut microbiome dysbiosis, setting the stage for human trials to investigate the role of these agents in the treatment of IBD among people with or without diabetes and obesity' (Arvanitakis, Theocharis, Popovic
Injection hesitancy is a real and documented barrier to GLP-1 adoption
Injecting on an empty stomach (at least 2-3 hours after the last meal) prevents elevated blood glucose or free fatty acids from blunting the GH release
The results of this analysis were combined, including the risk and incidence [32]